Conflict of interest: will it ever end?

Area of Science:

• Clinical Trials
• Drug Development
• Medical Research Ethics

Background:

• Investigator-industry financial relationships are disclosed in clinical trials.
• The effectiveness of these disclosures in mitigating bias is questioned.
• Recent pivotal phase III drug studies highlight conflict of interest concerns.

Purpose of the Study:

• To evaluate the adequacy of current disclosure practices for investigator-industry associations.
• To examine the impact of financial disclosures on the integrity of clinical trial data.
• To propose enhanced measures for safeguarding research objectivity.

Main Methods:

• Analysis of two pivotal phase III drug studies with reported conflict of interest issues.
• Review of existing literature on financial disclosures in clinical research.
• Examination of the nature of pecuniary and non-pecuniary associations.

Main Results:

• The benefits of disclosing investigator-industry associations may be limited in practice.
• Conflict of interest issues persist despite current disclosure protocols.
• The discussed studies indicate potential for bias influencing trial outcomes.

Conclusions:

• Current disclosure practices for investigator-industry relationships may be insufficient.
• A stronger separation, or firewall, between industry and investigators is needed.
• Implementing a firewall could enhance the credibility and objectivity of clinical trial findings.